Objectif(s) poursuivi(s)
Les activités de recherche du service de dermatologie du CHU de Nantes sont organisées selon 3 principaux axes :

1. développement et réalisation d’essais cliniques dans les cancers cutanés,
2. recherche translationnelle, axée majoritairement sur le microenvironnement tumoral ainsi que le transfert adoptif de lymphocytes dans le mélanome,
3. épidémiologie et prévention du mélanome et des cancers cutanés non-mélanome.

Collaboration(s) avec le(s) laboratoire(s)
BMS, ROCHE, MSD, Amgen, Novartis, Incyte, Pierre-Fabre oncologie

Site internet
http://www.crcina.org/recherche/departement-1-incit/equipe-02-clinical-and-translational-research-in-skin-cancer/

Principales publications
Hauschild A, Larkin J, Ribas A, Dréno B, Flaherty KT, Ascierto PA, Lewis KD, McKenna E, Zhu Q, Mun Y, McArthur GA. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials. JAMA Oncol. 2018 Oct 1;4(10):1382-1388. doi: 10.1001/jamaoncol.2018.2668. PubMed PMID: 30073321; PubMed Central PMCID: PMC6233771.

Dreno B, Thompson JF, Smithers BM, Santinami M, Jouary T, Gutzmer R, Levchenko E, Rutkowski P, Grob JJ, Korovin S, Drucis K, Grange F, Machet L, Hersey P, Krajsova I, Testori A, Conry R, Guillot B, Kruit WHJ, Demidov L, Thompson JA, Bondarenko I, Jaroszek J, Puig S, Cinat G, Hauschild A, Goeman JJ, van Houwelingen HC, Ulloa-Montoya F, Callegaro A, Dizier B, Spiessens B, Debois M, Brichard VG, Louahed J, Therasse P, Debruyne C, Kirkwood JM. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Jul;19(7):916-929. doi: 10.1016/S1470-2045(18)30254-7. Epub 2018 Jun 13. PubMed PMID: 29908991.

Knol AC, Nguyen JM, Pandolfino MC, Denis MG, Khammari A, Dréno B. PD-L1 expression by tumor cell lines: A predictive marker in melanoma. Exp Dermatol. 2018 Jun;27(6):647-655. doi: 10.1111/exd.13526. PubMed PMID: 29505109.

Dréno B, Ascierto PA, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Bartley K, Karagiannis T, Chang I, Rooney I, Koralek DO, Larkin J, McArthur GA, Ribas A. Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation-positive melanoma. Br J Cancer. 2018 Mar 20;118(6):777-784. doi: 10.1038/bjc.2017.488.Epub 2018 Feb 13. PubMed PMID: 29438370; PubMed Central PMCID: PMC5877437.

Delaunay T, Violland M, Boisgerault N, Dutoit S, Vignard V, Münz C, Gannage M, Dréno B, Vaivode K, Pjanova D, Labarrière N, Wang Y, Chiocca EA, Boeuf FL, Bell JC, Erbs P, Tangy F, Grégoire M, Fonteneau JF. Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells. Oncoimmunology. 2017 Dec 26;7(3):e1407897. doi: 10.1080/2162402X.2017.1407897. eCollection 2018. PubMed PMID: 29399408; PubMed Central PMCID: PMC5790392.

Simon S, Vignard V, Varey E, Parrot T, Knol AC, Khammari A, Gervois N, Lang F, Dreno B, Labarriere N. Emergence of High-Avidity Melan-A-Specific Clonotypes as a Reflection of Anti-PD-1 Clinical Efficacy. Cancer Res. 2017 Dec 15;77(24):7083-7093. doi: 10.1158/0008-5472.CAN-17-1856. Epub 2017 Dec 6. PubMed PMID: 29212853.

Herbreteau G, Vallée A, Knol AC, Théoleyre S, Quéreux G, Khammari A, Dréno B, Denis MG. Circulating tumour DNA: analytical aspects and clinical applications for metastatic melanoma patients. Ann Biol Clin (Paris). 2017 Dec 1;75(6):619-630. doi: 10.1684/abc.2017.1305. Review. PubMed PMID: 29192597.

Grob JJ, Mortier L, D’Hondt L, Grange F, Baurain JF, Dréno B, Lebbe C, Robert C, Dompmartin A, Neyns B, Gillet M, Louahed J, Jarnjak S, Lehmann FF. Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature. ESMO Open. 2017 Nov 14;2(5):e000203. doi: 10.1136/esmoopen 2017-000203. eCollection 2017. PubMed PMID: 29177094; PubMed Central PMCID: PMC5687540.

Wongchenko MJ, Ribas A, Dréno B, Ascierto PA, McArthur GA, Gallo JD, Rooney IA, Hsu J, Koeppen H, Yan Y, Larkin J. Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib. Pigment Cell Melanoma Res. 2018 Jul;31(4):516-522. doi: 10.1111/pcmr.12670. Epub 2017 Dec 10. PubMed PMID: 29156488.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun. 2017 Sep 19;8(1):592. doi: 10.1038/s41467-017-00608-2. PubMed PMID: 28928380; PubMed Central PMCID: PMC5605517.

de la Cruz-Merino L, Di Guardo L, Grob JJ, Venosa A, Larkin J, McArthur GA, Ribas A, Ascierto PA, Evans JTR, Gomez-Escobar A, Barteselli G, Eng S, Hsu JJ, Uyei A, Dréno B. Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. J Transl Med. 2017 Jun 24;15(1):146. doi: 10.1186/s12967-017-1246-0. PubMed PMID: 28646893; PubMed Central PMCID: PMC5483259.

Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group. Brentuximab vedotin or physician’s choice in CD30 positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017 Aug 5;390(10094):555 566. doi: 10.1016/S0140-6736(17)31266-7. Epub 2017 Jun 7. PubMed PMID: 28600132.

bWongchenko MJ, McArthur GA, Dréno B, Larkin J, Ascierto PA, Sosman J, Andries L, Kockx M, Hurst SD, Caro I, Rooney I, Hegde PS, Molinero L, Yue H, Chang I, Amler L, Yan Y, Ribas A. Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. Clin Cancer Res. 2017 Sep 1;23(17):5238-5245. doi: 10.1158/1078-0432.CCR-17 0172. Epub 2017 May 23. PubMed PMID: 28536307.